Skip to main content Skip to navigation
Hamburger Menu
Search icon
Country Selector Country Selector
Brazil (English)
Profile Icon Profile Icon
Sign-in/Register UserName
Products

Discover & Learn

Resources & Tools

Support

Search icon Search icon
Close Menu
      Alert Icon
      BV605 Mouse Anti-Human HLA-G
      Product Details
      Down Arrow Up Arrow


      BD OptiBuild™
      HLA-G; HLAG; MHC class I antigen G; MHC-G; sHLA-G
      Human (Tested in Development)
      Mouse IgG2a, κ
      HLA-G-transfected Cells
      Flow cytometry (Qualified)
      0.2 mg/ml
      AB_2875644
      Aqueous buffered solution containing ≤0.09% sodium azide.
      RUO


      Preparation And Storage

      Store undiluted at 4°C and protected from prolonged exposure to light. Do not freeze. The monoclonal antibody was purified from tissue culture supernatant or ascites by affinity chromatography. The antibody was conjugated to the dye under optimum conditions that minimize unconjugated dye and antibody.
      Show More blue down arrow Show Less blue up arrow

      Recommended Assay Procedures

      BD™ CompBeads can be used as surrogates to assess fluorescence spillover (Compensation).  When fluorochrome conjugated antibodies are bound to CompBeads, they have spectral properties very similar to cells.   However, for some fluorochromes there can be small differences in spectral emissions compared to cells, resulting in spillover values that differ when compared to biological controls.  It is strongly recommended that when using a reagent for the first time, users compare the spillover on cells and CompBead to ensure that BD Comp beads are appropriate for your specific cellular application.

      For optimal and reproducible results, BD Horizon Brilliant Stain Buffer should be used anytime two or more BD Horizon Brilliant dyes are used in the same experiment.  Fluorescent dye interactions may cause staining artifacts which may affect data interpretation.  The BD Horizon Brilliant Stain Buffer was designed to minimize these interactions.  More information can be found in the Technical Data Sheet of the BD Horizon Brilliant Stain Buffer (Cat. No. 563794/566349) or the BD Horizon Brilliant Stain Buffer Plus (Cat. No. 566385).

      Show More blue down arrow Show Less blue up arrow

      Product Notices

      1. The production process underwent stringent testing and validation to assure that it generates a high-quality conjugate with consistent performance and specific binding activity. However, verification testing has not been performed on all conjugate lots.
      2. Researchers should determine the optimal concentration of this reagent for their individual applications.
      3. An isotype control should be used at the same concentration as the antibody of interest.
      4. Caution: Sodium azide yields highly toxic hydrazoic acid under acidic conditions. Dilute azide compounds in running water before discarding to avoid accumulation of potentially explosive deposits in plumbing.
      5. For fluorochrome spectra and suitable instrument settings, please refer to our Multicolor Flow Cytometry web page at www.bdbiosciences.com/colors.
      6. Please refer to www.bdbiosciences.com/us/s/resources for technical protocols.
      7. BD Horizon Brilliant Stain Buffer is covered by one or more of the following US patents: 8,110,673; 8,158,444; 8,575,303; 8,354,239.
      8. Please refer to http://regdocs.bd.com to access safety data sheets (SDS).
      9. Please observe the following precautions: Absorption of visible light can significantly alter the energy transfer occurring in any tandem fluorochrome conjugate; therefore, we recommend that special precautions be taken (such as wrapping vials, tubes, or racks in aluminum foil) to prevent exposure of conjugated reagents, including cells stained with those reagents, to room illumination.
      10. CF™ is a trademark of Biotium, Inc.
      11. Although every effort is made to minimize the lot-to-lot variation in the efficiency of the fluorochrome energy transfer, differences in the residual emission from BD Horizon™ BV421 may be observed. Therefore, we recommend that individual compensation controls be performed for every BD Horizon™ BV605 conjugate.
      12. BD Horizon Brilliant Violet 605 is covered by one or more of the following US patents: 8,110,673; 8,158,444; 8,227,187; 8,455,613; 8,575,303; 8,354,239.
      Show More blue down arrow Show Less blue up arrow
      751657 Rev. 1
      Antibody Details
      Down Arrow Up Arrow
      87G

      The 87G monoclonal antibody specifically recognizes Human Leukocyte Antigen G (HLA-G) which is encoded by HLA-G (major histocompatibility complex, class I, G). HLA-G is a nonclassical Major Histocompatibility Complex class I (MHC-Ib) molecule that is structurally related to the classical MHC class Ia antigens (HLA-A, -B, -C). Several HLA-G isoforms have been described including transmembrane HLA-G1, -G2, -G3, -G4 and soluble HLA-G5, -G6, and -G7. The 87G monoclonal antibody reportedly recognizes a conformationally-dependent epitope on the heterodimeric transmembrane HLA-G1 and soluble HLA-G7 isoforms that consist of an HLA-G alpha chain and β2-microglobulin (β2m). HLA-G1 is variably expressed on placental trophoblast cells, thymic epithelial cells, activated monocytes, macrophages, dendritic cells, and tumor cells. Heterodimeric HLA-G shows limited variation and binds a limited variety of self-peptides derived from intracellular proteins including histones and ribosomal proteins. This molecule binds to inhibitory receptors such as CD85d, CD85j, and CD158d that are differentially expressed by NK cells, T cells, monocytes, dendritic cells, and B cells. This interaction exerts suppressive regulation of immune responses and is thought to help safeguard maternal tolerance of the fetus during pregnancy. The 4H84 monoclonal antibody that reportedly recognizes denatured forms of HLA-G1 and HLA-G2 has also been described.

      This antibody is conjugated to BD Horizon™ BV605 which is part of the BD Horizon Brilliant™ Violet family of dyes. With an Ex Max of 407-nm and Em Max of 602-nm, BD Horizon BV605 can be excited by a violet laser and detected with a standard 610/20-nm filter set. BD Horizon BV605 is a tandem fluorochrome of BD Horizon BV421 and an acceptor dye with an Em max at 605-nm. Due to the excitation of the acceptor dye by the green (532 nm) and yellow-green (561 nm) lasers, there will be significant spillover into the PE and BD Horizon PE-CF594 detectors off the green or yellow-green lasers. BD Horizon BV605 conjugates are very bright, often exhibiting brightness equivalent to PE conjugates and can be used as a third color off of the violet laser.

      751657 Rev. 1
      Format Details
      Down Arrow Up Arrow
      BV605
      The BD Horizon Brilliant Violet™ 605 (BV605) dye is part of the BD Horizon Brilliant Violet™ family of dyes. This tandem fluorochrome is comprised of a BV421 donor with an excitation maximum (Ex Max) of 407-nm and an acceptor dye with an emission maximum (Em Max) at 605-nm. BV605, driven by BD innovation, is designed to be excited by the violet laser (405-nm) and detected using an optical filter centered near 610-nm (e.g., a 610/20-nm bandpass filter). The acceptor dye can be excited by the yellow-green (561-nm) laser resulting in cross-laser excitation and fluorescence spillover. Please ensure that your instrument’s configurations (lasers and optical filters) are appropriate for this dye.
      altImg
      BV605
      Violet 405 nm
      407 nm
      605 nm
      751657 Rev.1
      Citations & References
      Down Arrow Up Arrow

      Development References (6)

      1. Dorling A, Monk NJ, Lechler RI. HLA-G inhibits the transendothelial migration of human NK cells. Eur J Immunol. 2000; 30(2):586-593. (Biology). View Reference
      2. King A, Allan DS, Bowen M, et al. HLA-E is expressed on trophoblast and interacts with CD94/NKG2 receptors on decidual NK cells. Eur J Immunol. 2000; 30(6):1623-1631. (Biology). View Reference
      3. Le Gal FA, Riteau B, Sedlik C, et al. HLA-G-mediated inhibition of antigen-specific cytotoxic T lymphocytes. Int Immunol. 1999; 11(8):1351-1356. (Biology). View Reference
      4. Lee N, Malacko AR, Ishitani A, et al. The membrane-bound and soluble forms of HLA-G bind identical sets of endogenous peptides but differ with respect to TAP association. Immunity. 1995; 3(5):591-600. (Immunogen: ELISA, Flow cytometry). View Reference
      5. Odum N, Ledbetter JA, Martin P, et al. Homotypic aggregation of human cell lines by HLA class II-, class Ia- and HLA-G-specific monoclonal antibodies.. Eur J Immunol. 1991; 21(9):2121-31. (Immunogen: Functional assay). View Reference
      6. Yang Y, Chu W, Geraghty DE, Hunt JS. Expression of HLA-G in human mononuclear phagocytes and selective induction by IFN-gamma.. J Immunol. 1996; 156(11):4224-31. (Clone-specific: Flow cytometry, Immunohistochemistry). View Reference
      View All (6) View Less
      751657 Rev. 1

      Please refer to Support Documents for Quality Certificates


      Global - Refer to manufacturer's instructions for use and related User Manuals and Technical data sheets before using this products as described


      Comparisons, where applicable, are made against older BD Technology, manual methods or are general performance claims.  Comparisons are not made against non-BD technologies, unless otherwise noted.

      For Research Use Only. Not for use in diagnostic or therapeutic procedures.

      Website Feedback